Home › Funds › Elmind Capital, LP › DSGN
Elmind Capital, LP position in DSGN
DESIGN THERAPEUTICS INC · Health Care
Elmind Capital, LP reported holding 107,900 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.6M, representing 0.39% of its reported portfolio and ranking #31 among its reported holdings. Elmind Capital, LP has disclosed DSGN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's DSGN position evolved
Elmind Capital, LP first disclosed a stake in DSGN in Q4 2025 at 207,900 shares (US$2.0M). The position peaked in Q1 2026 at 207,900 shares, worth US$2.2M. Across 3 filings, Elmind Capital, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 107,900 shares valued at US$1.6M — a reduction of -100,000 shares quarter over quarter.. Notable position changes include a 48% trim in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 207.90K | $1.95M | New |
| Q1 2026 | 207.90K | $2.21M | Hold |
| Q2 2026 | 107.90K | $1.56M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), BAKER BROS. ADVISORS LP (US$38.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- SR ONE CAPITAL MANAGEMENT, LP 6.53M sh · $94.44M · Q2 2026
- Logos Global Management LP 3.00M sh · $43.41M · Q2 2026
- BAKER BROS. ADVISORS LP 2.68M sh · $38.76M · Q2 2026
- Trails Edge Capital Partners, LP 2.00M sh · $28.96M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K sh · $12.52M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 282.56K sh · $4.09M · Q2 2026
- KVP Capital Advisors, LP 185.00K sh · $2.68M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held DSGN?
Elmind Capital, LP has disclosed DSGN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in DSGN?
As of Q2 2026, Elmind Capital, LP holds 107.90K shares of DSGN (DESIGN THERAPEUTICS INC), valued at $1.56M, representing 0.39% of its reported portfolio and ranking #31.
Has Elmind Capital, LP been buying or selling DSGN?
In the latest 13F filing (Q2 2026), Elmind Capital, LP reduced its position in DSGN. The position peaked in Q1 2026 at 207.90K shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BAKER BROS. ADVISORS LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.